drugset / Trial / NCT03997734

Tolerability, Safety and Pharmacokinetics of a Topical AB001 Patch in Healthy Subjects

NCT03997734 ↗

Phase 1 Completed 34 enrolled Frontier Biotechnologies Inc.
RandomizedParallel-groupTriple-blindTreatment

Summary

The study evaluates the safety, tolerability and pharmacokinetics of single and repeated doses of topical AB001 patch and the bioavailability relative to the oral capsule and topical positive comparative patch.

Timeline

Start
2019-06-24
Primary completion
2019-11-11
Completion
2019-11-11

Drugs

EvaluationDrugModalityDoseRoute
Subject AB001 Other / unclassified — Topical
Subject oral capsule Unknown — Oral

Indications